KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short-term Investments: 2009-2025

Historic Short-term Investments for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $88.6 million.

  • Rigel Pharmaceuticals' Short-term Investments rose 840.45% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.6 million, marking a year-over-year increase of 840.45%. This contributed to the annual value of $20.6 million for FY2024, which is 14.79% down from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Short-term Investments stood at $88.6 million, which was up 61.19% from $55.0 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Short-term Investments' 5-year high stood at $112.7 million during Q3 2021, with a 5-year trough of $9.4 million in Q3 2024.
  • Its 3-year average for Short-term Investments is $28.8 million, with a median of $20.6 million in 2024.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Short-term Investments plummeted by 77.82% in 2023, and later spiked by 840.45% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Short-term Investments (Quarterly) stood at $106.1 million in 2021, then crashed by 68.19% to $33.7 million in 2022, then decreased by 28.45% to $24.1 million in 2023, then dropped by 14.79% to $20.6 million in 2024, then soared by 840.45% to $88.6 million in 2025.
  • Its Short-term Investments stands at $88.6 million for Q3 2025, versus $55.0 million for Q2 2025 and $31.4 million for Q1 2025.